{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:08:30Z","timestamp":1791173310810,"version":"4.1.0"},"reference-count":18,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Persistence of alemtuzumab at lympholytic concentrations after reduced-intensity conditioning allogeneic stem cell transplantations (RITs) could impair immune reconstitution and reduce donor T-cell\u2013mediated graft-versus-leukemia\/lymphoma (GVL) effects, derived from the graft or subsequent adoptive immunotherapy. We have studied the pharmacokinetics of alemtuzumab in 2 different groups: RIT (100 mg alemtuzumab in vivo over 5 days) and myeloablative allografts (20 mg alemtuzumab added in vitro to the stem cells prior to return). Alemtuzumab concentrations in RIT patients were in excess of that required to kill infused donor CD52+ cells at the time of transplantation and remained at potentially lympholytic levels (&amp;gt; 0.1 \u03bcg\/mL) for approximately 56 days after transplantation, 26 days longer than for the myeloablative group. Total lymphocyte counts were significantly lower in the RIT group persisting beyond 6 months after transplantation (P = .005), and median absolute CD4 counts higher than 200 \u00d7 106\/L were delayed until 9 months after transplantation. (Blood. 2003;102:404-406)<\/jats:p>","DOI":"10.1182\/blood-2002-09-2687","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T02:12:56Z","timestamp":1047348776000},"page":"404-406","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":168,"title":["Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications"],"prefix":"10.1182","volume":"102","author":[{"given":"Emma C.","family":"Morris","sequence":"first","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals, London, United Kingdom; and Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peppy","family":"Rebello","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals, London, United Kingdom; and Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty J.","family":"Thomson","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals, London, United Kingdom; and Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl S.","family":"Peggs","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals, London, United Kingdom; and Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals, London, United Kingdom; and Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony H.","family":"Goldstone","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals, London, United Kingdom; and Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mackinnon","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals, London, United Kingdom; and Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Hale","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals, London, United Kingdom; and Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217555164100_REF1","doi-asserted-by":"crossref","unstructured":"Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood.2001;97: 631-637.","DOI":"10.1182\/blood.V97.3.631"},{"key":"2020021217555164100_REF2","doi-asserted-by":"crossref","unstructured":"Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood.1999;94: 3234-3241.","DOI":"10.1182\/blood.V94.9.3234"},{"key":"2020021217555164100_REF3","doi-asserted-by":"crossref","unstructured":"Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol.1998;16: 2817-2824.","DOI":"10.1200\/JCO.1998.16.8.2817"},{"key":"2020021217555164100_REF4","doi-asserted-by":"crossref","unstructured":"Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood.2002;99: 1071-1078.","DOI":"10.1182\/blood.V99.3.1071"},{"key":"2020021217555164100_REF5","doi-asserted-by":"crossref","unstructured":"Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy.2001;3: 261-267.","DOI":"10.1080\/146532401317070899"},{"key":"2020021217555164100_REF6","doi-asserted-by":"crossref","unstructured":"Brett S, Baxter G, Cooper H, et al. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting monoclonal antibody, CAMPATH-1H. Immunology.1996;88: 13-19.","DOI":"10.1046\/j.1365-2567.1996.d01-650.x"},{"key":"2020021217555164100_REF7","doi-asserted-by":"crossref","unstructured":"Isaacs JD, Wing MG, Greenwood JD, Hazleman BL, Hale G, Waldmann H. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol.1996;106: 427-433.","DOI":"10.1046\/j.1365-2249.1996.d01-876.x"},{"key":"2020021217555164100_REF8","doi-asserted-by":"crossref","unstructured":"Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature.1988;332: 323-327.","DOI":"10.1038\/332323a0"},{"key":"2020021217555164100_REF9","doi-asserted-by":"crossref","unstructured":"Tang SC, Hewitt K, Reis MD, Berinstein NL. Immunosuppressive toxicity of CAMPATH-1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma.1996;24: 93-101.","DOI":"10.3109\/10428199609045717"},{"key":"2020021217555164100_REF10","doi-asserted-by":"crossref","unstructured":"Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood.1998;91: 756-763.","DOI":"10.1182\/blood.V91.3.756"},{"key":"2020021217555164100_REF11","doi-asserted-by":"crossref","unstructured":"Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood.1983;62: 873-882.","DOI":"10.1182\/blood.V62.4.873.873"},{"key":"2020021217555164100_REF12","doi-asserted-by":"crossref","unstructured":"Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood.1997;89: 4531-4536.","DOI":"10.1182\/blood.V89.12.4531"},{"key":"2020021217555164100_REF13","doi-asserted-by":"crossref","unstructured":"Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood.1989;73: 1431-1439.","DOI":"10.1182\/blood.V73.6.1431.1431"},{"key":"2020021217555164100_REF14","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of CAMPATH-1H in delaying immune reconstitution. Blood.2002;99: 4357-4363.","DOI":"10.1182\/blood.V99.12.4357"},{"key":"2020021217555164100_REF15","unstructured":"Peggs K, Verfuerth S, Pizzey A, Khan N, Moss P, Mackinnon S. Cytomegalovirus-specific adoptive cellular therapy results in massive and persistent expansions of CMV-specific T-cells and significantly reduces the incidence of CMV reactivation following allogeneic transplantation. Blood.2001; 98: 779a."},{"key":"2020021217555164100_REF16","unstructured":"Perez-Simon JA, Kottaridis P, Martino R, et al. Reduced intensity conditioning (RIC) allogeneic transplantation with or without CAMPATH-1: comparison between two prospective studies in patients with lymphoproliferative disorders [abstract]. Blood.2001;98: 743a."},{"key":"2020021217555164100_REF17","doi-asserted-by":"crossref","unstructured":"Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood.2000;96: 2419-2425.","DOI":"10.1182\/blood.V96.7.2419"},{"key":"2020021217555164100_REF18","doi-asserted-by":"crossref","unstructured":"Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods.2002;260: 285-302.","DOI":"10.1016\/S0022-1759(01)00556-7"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/1\/404\/1688249\/h81303000404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/1\/404\/1688249\/h81303000404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T23:54:02Z","timestamp":1581551642000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/1\/404\/16799\/Pharmacokinetics-of-alemtuzumab-used-for-in-vivo"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-09-2687","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,1]]}}}